- Price
- $17.28
- Day
- -1.85%
- Mkt Cap
- $13.79B
- 52W Range
- $12.07 – $29.23
- Volume
- 7.34M
- Beta
- -1.24
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT
Bank of New York Mellon Corp purchased a new position in Summit Therapeutics PLC (NASDAQ: SMMT) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 431,299 shares of the company's stock, valued at approximately $6,284,000. Bank of New York Mellon Corp owned approximately
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
Summit Therapeutics is positioned as a high-conviction buy into the November 2026 FDA PDUFA decision for ivonescimab in NSCLC. SMMT's ivonescimab demonstrates robust PFS and statistically significant OS benefits in multiple Phase III trials, supporting best-in-class potential versus PD-1 monotherapy. Financials reflect intentional capital deployment, with $690M+ cash and 4–5 quarters of runway to fund late-stage clinical catalysts and regulatory milestones.
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading higher on Thursday after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial.
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China.